

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 87031

**Title:** Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03072664

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2023-07-21

**Reviewer chosen by:** Geng-Long Liu

**Reviewer accepted review:** 2023-08-09 01:39

**Reviewer performed review:** 2023-08-13 23:10

**Review time:** 4 Days and 21 Hours

Scientific quality	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish
Novelty of this manuscript	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Good <input type="radio"/> Grade C: Fair <input type="radio"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Good <input type="radio"/> Grade C: Fair <input type="radio"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	[ <input checked="" type="radio"/> ] Grade A: Excellent    [ <input type="radio"/> ] Grade B: Good    [ <input type="radio"/> ] Grade C: Fair [ <input type="radio"/> ] Grade D: No scientific significance
<b>Language quality</b>	[ <input checked="" type="radio"/> ] Grade A: Priority publishing    [ <input type="radio"/> ] Grade B: Minor language polishing    [ <input type="radio"/> ] Grade C: A great deal of language polishing    [ <input type="radio"/> ] Grade D: Rejection
<b>Conclusion</b>	[ <input checked="" type="radio"/> ] Accept (High priority)    [ <input type="radio"/> ] Accept (General priority) [ <input type="radio"/> ] Minor revision    [ <input type="radio"/> ] Major revision    [ <input type="radio"/> ] Rejection
<b>Re-review</b>	[ <input checked="" type="radio"/> ] Yes    [ <input type="radio"/> ] No
<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous    [ <input type="radio"/> ] Onymous
	Conflicts-of-Interest: [ <input type="radio"/> ] Yes    [ <input checked="" type="radio"/> ] No

#### SPECIFIC COMMENTS TO AUTHORS

This is a very interesting manuscript about EGFR T790M mutated in a colorectal cancer patient; and also the tumor of the patient response to osimertinib. This is rare case, not reported before in literature. Gene panel in advanced colorectal is critical important especially in the late line therapy. The limitations of the study are patients harboring EGFR T790M mutation or other activating mutations are not common.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 87031

**Title:** Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03270441

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2023-07-21

**Reviewer chosen by:** Geng-Long Liu

**Reviewer accepted review:** 2023-08-18 08:29

**Reviewer performed review:** 2023-08-22 10:02

**Review time:** 4 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The authors reported a case of sigmoid colon adenocarcinoma with hepatic metastases that had a T790M mutation and achieved good results after treatment with osimertinib. They illustrated a successful example of using large panel multi-gene sequencing assays to identify potential targets and find proper medicine on such diseases. A relatively rare precise treatment was successfully implemented for this case. However, I prefer to know the possible reason why an other case in the same type achieved only 95-day response form literature published (Line 3-4, the fourth paragraph of the part of Discussion).